(S)-1-异丙基氮杂丁烷-2-羧酸 | 255882-98-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-1-异丙基氮杂丁烷-2-羧酸
• 英文名称: (S)-1-Isopropylazetidine-2-carboxylic acid
• 英文别名: (2S)-1-propan-2-ylazetidine-2-carboxylic acid
• CAS: 255882-98-5
• 化学式: C₇H₁₃NO₂
• 分子量: 143.18
• InChiKey: QXSMFOUJZBBPIV-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20210106588A1

  公开（公告）日：2021-04-15

  The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

  这项发明涉及双环杂环化合物及其药物组合物，这些化合物是FGFR酶的抑制剂，可用于治疗与FGFR相关的疾病，如癌症。
• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150148327A1

  公开（公告）日：2015-05-28

  The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , C y , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了以下公式（I）的某些取代吡啶或其药学上可接受的盐，其中R1，R2，R3，R4，Rcy，Cy和t如本文所定义。 本发明还提供了包含这种化合物的制药组合物，并且提供了使用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
• SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150166486A1

  公开（公告）日：2015-06-18

  The invention provides certain substituted diazine and triazine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R cy , C y , and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了公式(I)（I）的某些取代的二嗪和三嗪化合物或其药学上可接受的盐，其中R1，R2，R3，R4，Rcy，Cy和t的定义如本文所述。本发明还提供包含这些化合物的制药组合物，以及使用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或病症的方法。
• Process for producing optically active N-substituted azetidine-2-carboxylic acid compound
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP0974670A2

  公开（公告）日：2000-01-26

  There is provided a process for producing an optically active N-substituted azetidine-2-carboxylic acid compound represented by the formula (2): by contacting a corresponding N-substituted azetidine-2-carboxylic acid ester of formula (2) with an enzyme derived from a microorganism selected from Arthrobacter SC-6-98-28 strain, Arthrobacter sp. ATCC21908 strain, Chromobacterium SC-YM-1 strain, and a mutant thereof. A process is also provided for preparing an optically active azetidine-2-carboxylic acid by eliminating the N-substituent of a N-substituted azetidine-2-carboxylic acid ester of formula (2).

  提供了一种生产具有光学活性的 N-取代氮杂环丁烷-2-羧酸化合物的工艺，该化合物由式（2）代表： 将相应的式(2)N-取代的氮杂环丁烷-2-羧酸酯与一种酶接触，该酶来源于一种微生物，该微生物选自节杆菌 SC-6-98-28 株、节杆菌 ATCC21908 株、色杆菌 SC-YM-1 株及其突变体。还提供了一种通过消除式（2）N-取代的氮杂环丁烷-2-羧酸酯的 N-取代基来制备光学活性氮杂环丁烷-2-羧酸的工艺。